Value of the Diagnostic-Driven Therapy with Voriconazole in Patients with Hematological Disorders Complicated by Invasive Fungal Disease.
10.19746/j.cnki.issn.1009-2137.2022.04.048
- Author:
Pei-Xun SU
1
;
Yong-Hua LI
2
Author Information
1. The First School of Clinical Medicine, Southern Medical University, Guangzhou 510080, Guangdong Province, China,Department of General Practice, General Hospital of Southern Theatre Command, Guangzhou 510030, Guangdong Province, China.
2. The First School of Clinical Medicine, Southern Medical University, Guangzhou 510080, Guangdong Province, China,Department of Hematology, General Hospital of Southern Theatre Command, Guangzhou 510030, Guangdong Province, China,E-mail: lyhood@163.com.
- Publication Type:Journal Article
- Keywords:
diagnostic-driven therapy;
empirical therapy;
hematological disorders;
invasive fungal disease;
voriconazole
- MeSH:
Antifungal Agents/therapeutic use*;
Hematologic Diseases/drug therapy*;
Humans;
Invasive Fungal Infections/drug therapy*;
Retrospective Studies;
Voriconazole/therapeutic use*
- From:
Journal of Experimental Hematology
2022;30(4):1272-1276
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the value of the diagnostic-driven therapy with voriconazole in patients with hematological disorders complicated by invasive fungal disease (IFD).
METHODS:A total of 111 patients with hematological disorders complicated by IFD, treated with voriconazole in the hematology department of the General Hospital of South Theatre Command from July 2019 to July 2020, were retrospectively analyzed to compare the differences between the empirical therapy and the diagnostic-driven therapy on the treatment time of voriconazole, hospitalization days and antifungal efficacy. SPSS 23.0 was used for statistical analysis of data.
RESULTS:Compared with the diagnostic-driven therapy group, the empirical therapy group had more IFD high-risk patients, including a higher proportion of agranulocytosis patients (95.2% vs 69.5%, P=0.003). However, there were no significant differences on the treatment time of voriconazole, hospitalization days and antifungal efficacy of voriconazole between the two groups.
CONCLUSION:Using diagnostic-driven therapy in relatively IFD low-risk patients can obtain similar therapeutic outcomes and prognosis as empirical therapy in high-risk patients. Either of two strategies can be used in clinical practice according to the individual conditions of patients.
